Skip to main content

Wegener's Granulomatosis

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
1
DaclizumabPhase 2Monoclonal Antibody1 trial
RituximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00072592Completed10Est. Aug 2005
NCT00040248Completed75Est. May 2005
Nippon Kayaku
Nippon KayakuJapan - Tokyo
1 program
1
GusperimusPhase 21 trial
Active Trials
NCT00530075Completed45Est. Feb 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Nippon KayakuGusperimus
Allergy TherapeuticsDaclizumab
Allergy TherapeuticsRituximab

Clinical Trials (3)

Total enrollment: 130 patients across 3 trials

NCT00530075Nippon KayakuGusperimus

Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis

Start: Dec 2003Est. completion: Feb 200645 patients
Phase 2Completed
NCT00040248Allergy TherapeuticsDaclizumab

Daclizumab to Treat Wegener's Granulomatosis

Start: Jun 2002Est. completion: May 200575 patients
Phase 2Completed
NCT00072592Allergy TherapeuticsRituximab

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

Start: Oct 2003Est. completion: Aug 200510 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.